Dr. Kun Chang| Urological Oncology | Best Researcher Award
Professional Summary 🌟
🎓 Ph.D. graduate in Urological Oncology with expertise in Ubiquitination and Tumorigenesis from Fudan University, Shanghai. 🏥 Currently, an Attending Urologist at Fudan University Shanghai Cancer Center, building on a comprehensive Residency experience from July 2018 to June 2021. 🌐 Actively engaged in groundbreaking research, exploring the mechanisms of SPOP-mediated non-degradable ubiquitination in prostate cancer. 🧪 Passionate about advancing understanding in the field and contributing to cutting-edge studies. 🚀 Excited to leverage skills and knowledge for further advancements in urological oncology. #UrologyExpert #ResearchInnovator
Professional Profiles
🎓 Education & Training
Ph.D., Sep 2015 – Jun 2018 Research Interests: Urological oncology, Ubiquitination, Tumorigenesis Fudan University, Shanghai, China. State Key Laboratory of Genetic Engineering, School of Life Sciences, Fudan University, Shanghai, P.R. China. M.D., Sep 2012 – Jun 2015 Research Interests: Urological oncology Fudan University, Shanghai, China
🔬 Researcher & Professional Experience
Residency at Fudan University Shanghai Cancer Center, July 2018-June 2021, Attending Urologist at Fudan University Shanghai Cancer Center, July 2021-
🔍 Charge Topic Researcher
Study on the mechanism of SPOP-mediated non-degradable ubiquitination modification of ARHGAP29 in regulating the Hippo pathway in prostate cancer. Shanghai Sailing Program (Grant No. 19YF 1408600) Study on the mechanism of SPOP-mediated ZMYND8 non-degradable ubiquitin-modification in prostate cancer to regulate DNA damage response. Natural Science Foundation of China (Grant No. 81902614)